- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Acrivon Therapeutics GAAP EPS of -$0.55 | 1 | Seeking Alpha | ||
| 13.08. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | 169 | GlobeNewswire (Europe) | Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and... ► Artikel lesen | |
| 13.08. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.06. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10 | 3 | Seeking Alpha | ||
| 15.05. | Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock | 2 | Investing.com | ||
| 14.05. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 575 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
| 05.05. | Piper Sandler sets $6 target for Acrivon stock, rates it Overweight | 1 | Investing.com | ||
| 25.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
| 07.04. | Acrivon appoints new chief medical officer to advance cancer trials | 1 | Investing.com | ||
| 07.04. | Acrivon ernennt neuen medizinischen Leiter zur Förderung von Krebsstudien | 2 | Investing.com Deutsch | ||
| 07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 166 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
| 07.04. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.03. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.03. | H.C. Wainwright maintains Acrivon stock Buy rating, $19 target | 2 | Investing.com | ||
| 28.03. | Acrivon Therapeutics reports Q4 results | 6 | Seeking Alpha | ||
| 27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 174 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen | |
| 27.03. | Acrivon Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright | 7 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,95 | -1,55 % | UBS stuft Biontech auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Biontech auf "Neutral" mit einem Kursziel von 115 US-Dollar belassen. Die Wachstumsaussichten für Comirnaty seien angesichts sich weltweit... ► Artikel lesen | |
| CUREVAC | 4,580 | -0,26 % | CureVac vor Kursexplosion - Analysten verdoppeln das Kursziel! | ||
| AMGEN | 245,20 | +0,31 % | Dividendenbekanntmachungen (22.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN AUSTRALIA EQUITY FUND INC US0030111035 0,12 USD 0,1033 EUR ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0646 EUR ADM... ► Artikel lesen | |
| NOVAVAX | 6,415 | -1,20 % | Milliarden-Verlustgefahr: Nach zweistelligem Absturz: Warum Novavax-Investoren weiter zittern müssen | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenNovavax steht unter massivem Druck: Ein Analysten-Downgrade, neue Milliarden-Schulden und Zweifel an der Impfstoff-Zukunft haben die Aktie... ► Artikel lesen | |
| BIOGEN | 114,20 | +0,57 % | Milliardenmarkt Multiple Sklerose - BioNxt Solutions, Biogen, Merck, Novartis | Multiple Sklerose (MS) ist eine entzündliche und chronische Erkrankung des zentralen Nervensystems im Gehirn und Rückenmark des Menschen. Dabei greift das Immunsystem durch eine Fehlregulation die eigenen... ► Artikel lesen | |
| MAINZ BIOMED | 1,660 | +0,61 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| VIKING THERAPEUTICS | 23,180 | -1,84 % | Why Viking Therapeutics Stock Popped Nearly 4% Today | ||
| INTELLIA THERAPEUTICS | 9,694 | -2,42 % | Cathie Wood's ARK shifts focus, buys Intellia stock, sells Roku and DraftKings | ||
| TEMPUS AI | 63,50 | 0,00 % | Tempus AI: Übernahme - Aktie rennt | Die Aktie des amerikanischen KI-Spezialisten Tempus AI kennt seit der Zahlenvorlage gefühlt nur den Weg nach oben. Gut zehn Prozent trennen den Titel nur noch vom bisherigen Rekordhoch bei 91,45 Dollar.... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,210 | -0,50 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Departure of Dr. Helen Thackray | RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,510 | -1,15 % | S&P Dow Jones Indices: Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 | NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,440 | +0,12 % | Sanofi snags BioMarin leader to take on CMO role 8 months after Berger's exit | ||
| EXELIXIS | 32,680 | +0,71 % | Exelixis to lay off 130 employees, shut down Pennsylvania site in post-pandemic downsizing | ||
| CARDIOL THERAPEUTICS | 0,920 | -1,81 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,131 | 0,00 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,330 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.